

Heimildir

1. Tryggvadóttir L, Tulinius H, Robertsson J McD. Familial and sporadic breast cancer cases in Iceland: A comparison related to ABO blood groups and risk of bilateral breast cancer. *Int J Cancer* 1988; 42: 499-501.
2. Eyfjörð JE, Thorlacius S. Genetic changes in breast carcinomas in an Icelandic population. *Pharmacogenetics* 1992; 2: 309-16.
3. Sneider NR, Williams WR, Chaganti SK. Genetic epidemiology of familial aggregation of cancer. *Adv Cancer Res* 1986; 47: 1-32.
4. Birch JM. Familial cancer syndromes and clusters. *Br Med Bull* 1994; 50: 624-39.
5. Tulinius H, Sigvaldason H, Olafsdóttir G, Tryggvadóttir L. Epidemiology of breast cancer in families in Iceland. *J Med Genet* 1992; 29: 158-64.
6. Ford D, Easton DF. The genetics of breast and ovarian cancers. *Br J Cancer* 1995; 72: 805-12.
7. Rahman N, Stratton MR. The Genetics of breast cancer susceptibility. *Annu Rev Genet* 1998; 32: 95-121.
8. Thorlacius S, Sigurdsson S, Bjarnadóttir H, Olafsdóttir G, Jonasson JG, Tryggvadóttir L, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. *Am J Hum Genet* 1997; 60: 1079-84.
9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997; 336: 1401-8.
10. Whittemore AS, Gong G, Itynre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from the U.S. population-based case-control study of ovarian cancer. *Am J Hum Genet* 1997; 60: 469-504.
11. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - Effects of prophylactic mastectomy and oophorectomy of life expecting among women with BRCA1 or BRCA2 mutations. *N Engl J Med* 1997; 336: 1465-71.
12. Thorlacius S, Struewing JP, Hartge P, Olafsdóttir GH, Sigvaldason H, Tryggvadóttir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. *The Lancet* 1998; 352: 1337-9.
13. Baum A, Friedman AL, Zakowski SG. Stress and genetic testing for disease risk. *Health Psychology* 1997; 16: 8-19.
14. Burke W, Daly M, Garber J, Botkin J, Kahn M, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. *JAMA* 1997; 277: 997-1003.
15. Lerman C, Croyle R. Emotional and behavioral responses to genetic testing for susceptibility to cancer. *Oncology* 1996; 10: 191-5.
16. Lerman C, Seay J, Balslem A, Audrian J. Interest in genetic testing among first-degree relatives of breast cancer patients. *Am J Med Genet* 1995; 57: 358-92.
17. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. *Am J Med Genet* 1997; 68: 43-9.
18. Lerman C, Daly M, Masny A, Balslem AM. Attitudes about genetic testing for breast-ovarian cancer susceptibility. *J Clin Oncol* 1994; 12: 843-50.
19. Struewing JP, Lerman C, Kase RG, Gianbarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. *Cancer Epidemiol Biomarkers Prev* 1995; 4:169-73.
20. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. *JAMA* 1996; 275: 1885-92.
21. Lerman C, Schwartz M. Adherence and psychological adjustment among women at high risk for breast cancer. *Breast Cancer Research and Treatment* 1993; 28: 145-55.
22. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. *Arch Intern Med* 1994; 154: 609-16.
23. Croyle R, Lerman C. Interest in genetic testing for colon cancer susceptibility: cognitive and emotional correlates. *Prevent Med* 1993; 22: 284-92.
24. Lerman C, Daly M, Sands C, Balslem AM, Lustbader E, Heggan T, et al. Mammography adherence and psychological distress among women at risk for breast cancer. *J Natl Cancer Inst* 1993; 85: 1074-80.
25. Stefanek ME, Wilcon P. First degree relatives of breast cancer patients: screening practices and provision of risk information. *Cancer Detect and Prevent* 1991; 15: 379-84.
26. McCaul KD, Schroeder DM, Reid PA. Breast cancer worry and screening: some prospective data. *Health Psychology* 1996; 15: 430-33.
27. Haily BJ. Family history of breast cancer and screening behavior: an inverted U-shaped curve? *Med Hypotheses* 1991; 36: 397-403.
28. Valdimarsdóttir HB, Bovbjerg D, Brown K, Jacobsen P, Schwartz MD, Bleiker E, et al. Cancer-specific distress is related to women's decisions to undergo BRCA1 testing. *Cancer Res Thera* 1998; 28: 1-3.
29. Jacobsen PB, Valdimarsdóttir HB, Brown KL, Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. *Psychosom Med* 1997; 59: 459-66.
30. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. *Psychosom Med* 1979; 41: 209-18.
31. Fries, MH, Murphy KM, Flanagan J, Nunes M, McClellan D, Barholomew D. Patient indications for mutation testing after referral for genetic counseling for breast/ovarian cancer. *Am J Hum Genet* 1997; 61: A384.
32. Carter CL, Hailey BJ. Psychological issues in genetic testing for breast cancer. *Women & Health* 1999; 28: 73-91.
33. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* 1991; 48: 323-42.
34. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? What are the choices? *JAMA* 1993; 269: 1975-80.
35. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, et al. Effects of individualized breast cancer risk counselling: a randomized trial. *J Natl Cancer Inst* 1995; 87: 286-92.

Fræðigreinar íslenskra lækna í erlendum tímaritum

Getið er fræðigreina. Sendið heiti greinar, nöfn höfunda og birtingarstað. Miðað er við greinar sem birst hafa á yfirstandandi og síðasta ári. Til glöggvunar verður íslenskra höfunda getið með fornafni þótt svo hafi ekki verið við birtingu.

* Ehnebom J, Björquist P, Ólöf Sigurðardóttir, Deinum J. *Characterization of the interaction of plasminogen activator inhibitor type 1 with vitronectin by surface plasmon resonance*. *Fibinolysis & Proteolysis* 2000; 14: 47-57.